SightfileU.S. market data from official filings

Companies › AMLX

AMYLYX PHARMACEUTICALS INC (AMLX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001658551 · EDGAR filings · Updated 2026-07-13

AMYLYX PHARMACEUTICALS INC (AMLX) has reported institutional ownership of 102.7%, with 171 institutional managers holding positions valued at $1.59B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
102.7%
Institutional managers
171
Reported 13F value
$1.59B
Insider activity
44 trans.
−$7.55M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, AMYLYX PHARMACEUTICALS INC has 171 institutional holders and institutional ownership of 102.7%.

Insider activity

Insiders reported 44 transactions (1 buys, 32 sells) across 7 reporting insiders, with a net reported value of −$7.55M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2023-03-13 (recurring since 2022-03-31) — source filing. The authoritative details are those stated in the filing itself.

Related companies

ARTIVION INC (AORT) · TREVI THERAPEUTICS INC (TRVI) · HEARTFLOW INC (HTFL) · IMMUNOCORE HLDGS PLC (IMCR) · MBX BIOSCIENCES INC (MBX) · HARMONY BIOSCIENCES HLDGS IN (HRMY)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.